HLA-Independence & Potency Functional Analysis Services

Online Inquiry

Background Service What We Can Offer Workflow Specialty Services Highlights FAQs Contact

Creative Biolabs provides HLA-Independence & Potency Functional Analysis Services to address challenges in T-cell therapy development, including tumor antigen escape, limited T-cell persistence, and the MHC-restriction constraints associated with conventional TCR-T approaches. These services support the development of universal, off-the-shelf T-cell therapeutics through optimized T cell receptor fusion construct (TRuC) engineering and comprehensive cytokine profiling. By delivering robust functional validation and potency characterization, Creative Biolabs enables reliable candidate evaluation and supports the confident transition of next-generation immunotherapy programs from laboratory discovery to clinical development.

Introduction

Current immunotherapy is often limited by MHC restriction and the phenomenon of antigen escape. Recent literature indicates that TRuCs effectively reprogram the intact TCR complex to recognize tumor surface antigens in an HLA-independent manner. Unlike traditional CARs, TRuCs become functional components of the TCR, utilizing physiological signaling to achieve potent anti-tumor activity with significantly lower cytokine release. Published research demonstrates that optimizing subunit pairings and co-expressing cytokines like IL-7 and CCL21 robustly controls tumor recurrence.

Service

Creative Biolabs provides a robust analytical suite designed to validate that your engineered T cells function independently of Human Leukocyte Antigen (HLA) restriction while maintaining superior lytic potency. Our service ensures that your TRuC-T or CAR-T candidates can recognize tumor surface antigens directly, bypassing the complexities of MHC presentation that often lead to immune evasion.

Our HLA Independence Verification Platforms include antigen-specific cytotoxicity assays, gene-edited tumor cell models, and co-culture systems. Our Functional Potency Evaluation Platforms support real-time killing assays, multiplex cytokine profiling, and flow cytometry analysis. Immune Cell Functional Characterization assesses proliferation, signaling, and phenotype. These complementary approaches enable multidimensional evaluation of immune therapeutic candidates.

Discover How We Can Help - Request a Consultation.

What We Can Offer

Creative Biolabs integrates multiple experimental platforms designed to characterize immune recognition mechanisms and functional efficacy while maintaining flexibility for diverse therapeutic modalities.

HLA Independence Verification Platforms	Functional Potency Evaluation Platforms
Antigen-specific cytotoxicity assays using HLA-diverse target cell panels. Gene-edited tumor cell models with defined antigen or HLA expression profiles. Co-culture systems for evaluating antigen-dependent immune activation.	Real-time tumor-cell killing assays for dynamic cytotoxicity measurement. Cytokine secretion profiling using multiplex immunoassays. Immune activation marker analysis via flow cytometry.
Immune Cell Functional Characterization
Effector cell proliferation and persistence analysis. Tumor-engagement signaling assessment. Immune cell phenotype and activation state profiling.

Our Workflow

Required Starting Materials:

Target cell lines expressing the antigen of interest.
Genetic constructs or lentiviral vectors encoding your specific TRuC or CAR sequences.
Baseline performance data from initial T cell transduction experiments.

Workflow of HLA-Independence & Potency Functional Analysis. (Creative Biolabs Original)

Final Deliverables:

A comprehensive Technical Validation Report including real-time kill-curve data and receptor stoichiometry analysis.

Raw data files from flow cytometry.

High-resolution imaging of T cell-tumor synapses and migration assays.

Specialty Services

HLA-Independent Killing Assay

We verify non-MHC-restricted tumor lysis using diverse cancer cell lines. This service quantifies the direct cytotoxic efficiency of TRuC-T cells, ensuring potent anti-tumor responses regardless of the patient's HLA haplotype.

Comparative Cytokine Release Profiling

Our multiplex assays provide detailed mapping of Th1/Th2 cytokine signatures. We compare TRuC-T profiles against standard CAR-T benchmarks to evaluate safety, activation kinetics, and the risk of cytokine release syndrome (CRS).

Core Benefits

Flexible assay design tailored to diverse therapeutic formats such as engineered immune cells, antibody-based immune modulators, and other targeted biologics.
Advanced cellular analysis platforms enabling multiparametric functional profiling, immune cell phenotyping, and real-time cytotoxicity monitoring.
Customized experimental strategies are designed according to specific project goals, antigen targets, and therapeutic development stages.
High-quality data generation and interpretation, delivering reliable quantitative results to support candidate selection and mechanism validation.

FAQs

Q1: How do you confirm that the TRuC has actually integrated into the endogenous TCR?

A1: We visualize the native TCR complex. A successfully integrated TRuC will show a distinct shift in molecular weight (approximately 450 kDa), confirming it has become a structural part of the receptor.

Q2: Can your potency assays distinguish between different costimulatory domains?

A2: Yes. Our platform compares TRuC-mediated signaling against second-generation CARs. We provide detailed phosphorylation data for CD3 epsilon and LAT to map the exact signaling quality of your construct.

Q3: What measures are taken to ensure the HLA-independence of the receptor?

A3: We utilize MHC-deficient cell lines that still express the target antigen. If your T cells successfully lyse these targets, it provides definitive proof of HLA-independent recognition.

Q4: How do you evaluate the risk of CRS?

A4: While we do not perform clinical diagnosis, our assays measure a broad panel of pro-inflammatory cytokines. TRuC-T cells typically show a "gentler" signaling profile and lower cytokine release than CAR-T cells, which is a key safety indicator.

Partner with Us

Creative Biolabs offers world-class HLA-Independence & Potency Functional Analysis Services, providing the scientific rigor needed to validate next-generation T cell therapies. From receptor stoichiometry to real-time cytotoxicity, we ensure your immunotherapy platform is both universal and high-performing. We offer unparalleled expertise in optimizing subunit pairings to maximize receptor stability and anti-tumor persistence. For detailed project discussions and technical inquiries, please contact us.

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.